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FLOW-THROUGH FILTER TO REMOVE 
ALUMINUM FROM MEDICAL SOLUTIONS 
This utility patent application claims the benefit of priority 
in U.S. Provisional Patent Application Ser. No. 61/768,006 
filed on Feb. 22, 2013 and is a continuation-in-part of U.S. 
patent application Ser. No. 13/278,498, filed on Oct. 21, 2011, 
now U.S. Pat. No. 9,139,456, which is a continuation-in-part 
2 
TABLE !-continued 
Alwninwn content of the most contaminated SVP solutions 
Solution Aluminum concentration (micrograrns/L) 
Potassium Acetate 
Sodium acetate 
42 and 11 to 11201 
83 and 54 to 138 1 
1From Poole et al., Pediatr. Gastroenterol. Nutr. 2010, 50: 208; Poole et al., J. Pediatr. 
Pharmacal. Ther. 2011, 16: 92. 
of U.S. patent application Ser. No. 13/052,477, filed on Mar. 10 
21, 2011 which is now issued U.S. Pat. No. 8,066,883 and is 
2From Beaney and Smeaton, Congress of the EuropeanAssociation ofHospital Pharmacists, 
2010. 
3From de Oliveira et al., JPEN JParenterEnteral Nutr 2010,34:322-328. 
4FromAdvenier et al., J. Pediatr. Gastroenterol. Nutr. 2003,36: 448. 
a divisional of U.S. patent application Ser. No. 12/104,066, 
filed on Apr. 16, 2008 which is now issued U.S. Pat. No. 
7,932,326, the entirety of the disclosures of which are incor-
porated herein by reference. 
TECHNICAL FIELD 
This document relates generally to filter assemblies for 
removing metal ions from a solution and, more particularly, to 
a filter assembly capable of removing trivalent ions, such as 
aluminum, and tetravalent metal ions, from medical solu-
tions. 
BACKGROUND 
15 
Because of the relative volumes of each of these solutions 
included in a typical PN preparation, most of the final AI 
content originates from the calcium gluconate SVP solution. 
It is noteworthy that the AI content of calcium gluconate can 
vary widely, depending on the commercial provider. 
Reported AI concentrations range from 1920 to 19,400 micro-
grams/L. At a typical concentration of 4,000 micrograms/L, it 
20 is estimated that calcium gluconate contributes about 80% of 
the aluminum in the final PN solution (Mouser eta!., Am. J. 
Health-Syst. Pharm., 1998, 55: 1071). 
The FDA has formally recognized the problem of potential 
AI toxicity to premature infants. It has established a safe level 
25 of AI exposure as 4 to 5 micrograms/kg/d. However, it is 
widely recognized that currently the U.S. pharmaceutical 
industry cannot supply SVP component solutions that allow 
pediatric pharmacists to prepare PN solutions that meet this 
exposure limit. 
Other patient populations at risk include, but are not lim-
ited to, children with malabsorption syndrome, dialysis 
patients, elderly patients (due to a weakened GI protective 
barrier and/or normal renal function deterioration) and burn 
patients (due to Al-contaminated albumin to maintain oncotic 
Aluminum (AI) is a common contaminant in many medical 
solutions. This is in part the result of the widespread distri- 30 
bution of aluminum in the environment. In addition, some 
medical solutions contain compounds that react strongly with 
aluminum and extract this metal from the surroundings, e.g. 
from the walls of glass containers. This strong binding 
increases the AI contamination and makes it much more dif-
ficult to remove the aluminum from these solutions. 
35 pressure). In addition, critically ill infants and children 
require parenteral calcium replacement because of hypocal-
cemia, especially after cardiac surgery. More specifically, the 
amount of calcium required, provided as calcium gluconate, 
would lead to exposure to much greater than 5 micrograms of 
Healthy adults are generally protected against oral alumi-
num toxicity by the fact that less than 1% of an oral dose of 
aluminum is absorbed from the intestine. In addition, the 
urinary excretion of aluminum is relatively effective for per-
sons with normal kidney function. 
There is a special concern regarding aluminum exposure to 
premature neonates. These infants routinely require several or 
more days of parenteral nutrition (PN) until they can tolerate 
oral feeding. The PN bypasses the normal protection associ-
ated with low intestinal absorption of AI. In addition, these 
infants often have underdeveloped kidney function (the pri-
mary route of AI elimination), which impedes the excretion of 
the aluminum contained in the PN solution. 
It is well known that some of the small volume parenteral 
(SVP) solutions used to prepare the final PN solutions are 
heavily contaminated with aluminum. Poole, co-workers and 
others have extensively documented the AI content of SVP 
solutions, as shown in Table 1. 
TABLE 1 
Aluminwn content of the most contaminated SVP solutions 
Solution Aluminum concentration (micrograrns/L) 
Calcium gluconate 
and 19,4003 
Potassium phosphate 
Sodium Phosphate 
Multi-trace elements 
Potassiwn Lactate 
3234 and 1920 to 34951,4900 (new) and 
6145 (old glass arnpoules)2 , 9205 
8280 and 3650 to 16,820 1 
622 and 17 to 3281 1 
414 and 101 to 739\ 1049 and 2065 3 
15004 
40 aluminum per kg per day. Removal of aluminum from these 
parenteral infusions would minimize potential aluminum-
induced toxicities. 
Disclosed herein is a single-use filter to remove aluminum 
from a solution as it passes through the filter. The body of the 
45 filter is filled with a specialized chelator, such as trihydrox-
amate chelating resin, described in our previous U.S. Pat. 
Nos. 7,932,326 and 8,066,883 and U.S. patent application 
Ser. No. 13/278,498 the full disclosures of which are incor-
porated herein by reference. The other components of the 
50 filter are designed to produce a controlled fluid flow rate, 
using a partially evacuated vial and a flow restriction/flow 
controller tube that has an internal diameter and length, that 
when paired with the extent of vacuum in the partially evacu-
ated vial, achieves a desired flow rate. The filter is designed to 
55 connect to the evacuated vial and the vial of the source SVP 
solution. 
Chelating resins are not new. Chelex 1 00® is a polystyrene 
resin which has iminodiacetic acid functional groups 
covalently linked to the resin. It is relatively non-selective, 
60 and thus is widely used to bind a large number of metal ions. 
However, we have determined that this type of generic chelat-
ing resin is not effective for removing aluminum from solu-
tions such as calcium gluconate. 
The concept of a flow-through filter for removing contami-
65 nants from aqueous solutions is also widely used. There are 
many examples of point-of-use filters for home faucets to 
remove both metal ions and organic contaminants. These 
US 9,259,670 B2 
3 
typically remove metal ions by simple cation exchange. Thus 
they are not designed to compete against strong Al-binding 
ligands in the solution. More specialized chelating resins 
have been used in filters in research labs, but they have not 
been applied to the removal of aluminum from SVP solutions. 
Flow-through filters have been used in medical settings. 
4 
still other different embodiments and their several details are 
capable of modification and various obvious aspects. Accord-
ingly, the drawings and descriptions will be regarded as illus-
trative in nature and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The chelating agent desferrioxamine has been physically 
imbedded into a hollow-fiber filter for the extracorporeal 
removal of iron and aluminum from blood during hemodialy-
sis. Desferrioxamine has also been covalently bound to silica 10 
for the extracorporeal removal of metal ions from blood. 
Neither of these filters has been suggested for use in a phar-
maceutical setting for removing aluminum from SVP solu-
tions. 
The accompanying drawings incorporated herein and 
forming a part of the specification, illustrate several aspects of 
the filter assembly and system and together with the descrip-
tion serve to explain certain principles thereof. In the draw-
ings: 
FIG.1 is an exploded perspective view of the flow-through 
filter assembly. 
15 
SUMMARY 
FIG. 2 is a perspective view of the system for removing a 
trivalent or tetravalent metal ion from a solution. 
FIG. 3 is a detailed cross-sectional view illustrating the 
filter assembly. 
FIG. 4 is a graph of flow rate versus restrictor tube length 
20 for a flow restrictor tube of0.005" (0.127 mm) diameter at a 
draw pressure of 88,046.11 pascal (26 inHg) 
In accordance with the purposes noted above, a flow 
through filter assembly is provided for removing trivalent and 
tetravalent metal ions from a solution. In one embodiment, 
the flow through assembly includes a housing containing a 
hydroxamate chelating resin. The housing has an inlet and an 
outlet. A first vial connector is provided in fluid communica-
tion with the inlet. A second vial connector is provided in fluid 
communication with the outlet. Further the filter assembly 25 
includes a flow controller for limiting flow through the hous-
ing to a predetermined rate. In one useful embodiment that 
predetermined rate is less than 2.0 ml/min. In another useful 
embodiment the predetermined rate is less than 1.0 ml/min. In 
yet another useful embodiment that predetermined rate is 30 
about 1.0 ml/min. 
Reference will now be made in detail to the present pre-
ferred embodiments of the flow-through filter assembly and 
system illustrated in the accompanying drawings. 
DETAILED DESCRIPTION 
Reference is now made to FIG. 1 generally illustrating the 
flow-through filter assembly 10 for removing trivalent and 
tetravalent metal ions from a solution. The flow-through 
assembly 10 includes a housing 12 containing a chelating 
In one useful embodiment the first container connector is a 
vented spike and a first set of connector clips. In another 
useful embodiment the second container connector is a non-
vented spike and a second set of connector clips. The second 
vial has a negative interior pressure before the non-vented 
spike is inserted into the second vial. 
In accordance with an additional aspect a system is pro-
vided for removing a trivalent or tetravalent metal ion from a 
solution. The system comprises a first vial including a solu-
tion from which the trivalent or tetravalent metal ion is to be 
removed and a second vial for receiving a treated solution. 
The second vial has a negative interior pressure. Further the 
system includes a filter assembly for capturing the trivalent or 
tetravalent metal ion. The filter assembly is connected 
between the first and second vials. 
The filter assembly includes a first connector for the first 
vial and a second connector for the second vial. The first 
connector is a vented spike and a first clamp. The second 
connector is a non-vented spike and a second clamp. 
In accordance with yet another aspect, a flow-through filter 
assembly for removing metal ions from a medical solution, 
including aluminum ions, comprised of a housing including a 
medical solution inlet, an aluminum metal ion capturing 
agent having anAl-binding constant of at least approximately 
1020 held in the vessel and a treated medical solution outlet. 
The treated medical solution outlet is positioned relative to 
the medical solution inlet to allow flow of medical solution 
through the filter assembly without a mechanical pump. Fur-
ther, the assembly includes a flow controller for maintaining 
a rate of flow of medical solution through the filter assembly 
that allows capture of aluminum metal ions by the capturing 
agent. 
In the following description there are shown and described 
a number of different embodiments of a flow-through filter 
assembly and an associated system. It should be realized that 
the flow-through filter assembly and system are capable of 
agent or resin having an Al-binding constant of at least 
approximately 1 020 . In one useful embodiment that chelating 
agent is a trihydroxamate chelating resin. It should be appre-
35 ciated, however, that other chelating agents/resins may be 
used including, but not limited to, desferrioxamine chelating 
resin, tetrahydroxamate chelating resin, hydroxypyridinone 
chelating resin, aminocarboxylate chelating resin, catechol 
chelating resin, poly-carboxylate chelating resin and mix-
40 tures thereof. 
As further illustrated in FIG. 1, the flow-through filter 
assembly 10 includes a first container connector 14 at a first 
end and a second container connector 16 at a second end. In 
one possible embodiment the first container connector 14 is 
45 comprised of a vented spike 15 (note vent 18) and a first set of 
connector clips or clamp 38. In one possible embodiment the 
second container connector 16 comprises a non-vented spike 
17 and a second set of connector clips or clamp 40. 
The housing 12 contains the upper resin frit 24. The upper 
50 membrane housing 20 holds the lower resin frit 26. The resin 
is held between frits 24 and 26 during use of the filter assem-
bly 10 (see also FIG. 3). 
The filter assembly 10 also includes a lower membrane 
housing 28 including a grating 30 that supports a 0.2 or 0.45 
55 micron filter membrane 32. That membrane 32 functions to 
make certain that no particulates from the chelating agent or 
resin in the housing 12 are carried into the treated solution that 
is collected in the second container 104 (FIG. 2). Such a filter 
membrane 32 may be built-in as an integral component of the 
60 filter assembly 10. Alternatively, a 0.2 or 0.45 micron filter 
cartridge may be inserted between the housing 12 and the 
lower, non-vented spike 17. 
As further illustrated in FIGS. 1 and 3, a flow controller 34 
is provided within the control tube aperture 36 of the non-
65 vented spike 17. This flow controller 34 functions to limit the 
flow of solution through the filter assembly 10 to a rate of 
between 0.1 and 10 ml/min. In another embodiment the flow 
US 9,259,670 B2 
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selected to produce the appropriate flow rate for efficient 
aluminum removal from the targeted medical solution, in 
concert with the level of reduced pressure in the second con-
tainer, and other components of the filter 10. More specifi-
cally, a larger inner diameter flow restriction/flow controller 
tube 34 provides a faster flow rate. In contrast, a smaller inner 
diameter flow restriction/flow controller tube 34 provides a 
slower flow rate. 
Still more specifically, the flow restrictor tube 34 of the 
controller 34limits the rate of flow to less than 2.0 ml/min. In 
another embodiment the flow controller 34 limits the rate of 
flow to less than 1.0 ml/min. In yet another, the flow controller 
34limits the rate of flow to about 1.0 ml/min. In the illustrated 
embodiment, the flow controller 34 is a flow restrictor tube 
with an internal flow passage 35. It should be appreciated that 
the flow controller 34 does not have to be a tube, it can be 
molded directly into the spike 17, or a hole could be drilled in 
the spike to create a tube (passage) for fluid flow. The selected 
flow rate insures that there is sufficient time for trivalent and 
tetravalent metal ions in the solution to be captured by the 
chelating agent in the housing 12 as the solution flows 
through the housing 12. 
10 illustrated embodiment includes the flow passage 35 which 
has a predetermined length L of between about 5 mm and 
about 20 mm and a predetermined diameter ofbetween about 
0.0508 mm and about 0.1778 mm. Further the second con-
As previously noted, it should be appreciated that the first 
container connector 14 includes the first set of clips 38 and the 15 
second container connector 16 includes the second set of clips 
40. More specifically, the first set of clips 38 is engineered to 
snuggly clip onto the caps of a commercial container of SVP 
solution while the second set of clips 40 is engineered to 
snuggly clip onto an appropriately sized evacuated container 20 
so that the working system 100 (see FIG. 2) can be assembled 
conveniently and quickly and with no other clamping devices. 
More specifically, with reference to FIG. 2, the system 100 
includes: (a) a first vial or container 102 including a solution 
from which the trivalent or tetravalent ion is to be removed; 25 
(b) a second vial or container 104 for receiving a treated 
solution; and (c) the filter assembly 10 for capturing the 
trivalent or tetravalent metal ion. More specifically, as shown 
in FIG. 1 the clips 38 at the first end of the filter assembly 10 
engage a cap 106 (FIG. 2) of the firstcontainer102 effectively 30 
holding the vented spike 15, that is inserted into the vial 
through a puncturable seal in the cap, in fluid communication 
with the solution contained in the container. Similarly, the 
second set of clips 40 at the second end of the filter assembly 
tainer 104 has a negative interior pressure P ofbetween about 
84,659.72 pascal and about 94,818.88 pascal. The difference 
in the ambient pressure provided in the first container 102 by 
the vent 18 on the spike 15 and the negative pressure in the 
second container 104 functions to pull the solution through 
the filter assembly 10, including the flow passage 35. Thus, it 
should be appreciated that the flow passage length L, the flow 
passage diameter D and the second container interior pressure 
P function together to provide the desired rate of flow of 
solution through the filter assembly 10. 
Accordingly, the filter assembly 10 is engineered to pro-
vide the proper flow rate for removing the desired trivalent 
and/or tetravalent metal ions from the solution being treated. 
The operator does not need to adjust any pumps or monitor 
any equipment to provide the required flow rate. Thus, proper 
filtering of trivalent and tetravalent metal ions from the solu-
tion is ensured with minimal potential for any error. 
The following examples are presented to further illustrate 
the flow-through filter 10 and system 100. 
EXAMPLE 
Removal of AI from Commercial Calcium Gluconate 
Solutions 
We have prepared a filter assembly 10 specifically engi-
40 neered for the removal of AI from calcium gluconate. The 
upper connector 14 is engineered to fit the neck of standard 
10, 50 and 100 ml vials 102 of calcium gluconate. 
10 engage the cap 108 of the second container 104 effectively 35 
holding the non-vented spike 17, that is inserted into the vial 
through a puncturable seal in the cap, in fluid communication 
with the interior chamber of that container. The vent 18 to 
ambient atmosphere provided on the vented spike 15 works in 
conjunction with the negative pressure in the chamber of the 
second container 104 to produce a steady flow of solution 
from the first container 102 through the filter assembly 10 
including the chelating agent or resin held in the housing 12 
and the 0.2 or 0.45 micron membrane 3 2 to the chamber of the 
container 104. It should be appreciated that the chelating 
agent or resin in the housing 12 is specifically designed for 
high aluminum binding affinity enabling efficient extraction 
The trihydroxamate chelating resin was initially tested in 
stirred, batch extractions to establish its ability to remove AI 
of aluminum even from solutions that contain high concen-
trations of competing aluminum complexing agents such as 
gluconate or phosphate. 
45 from calcium gluconate. A 1 g sample of resin was added to 
100 ml of commercial calcium gluconate solution that was 
gently agitated by an overhead stirrer. In this configuration, 
the resin removed 80% of the AI. Based on the Al-binding 
constants of gluconate, the binding constant of the ligand 
50 immobilized on the resin was calculated to be 1020.4. 
Approximately 1 g ofligand was loaded into a housing 12, 
and a calcium gluconate solution was pulled through the filter 
by an evacuated collection vial 104. The fraction of AI 
removed at various flow rates was measured. Aluminum 
55 removal is inversely related to flow rate. The flow can be 
changed by changing the inner diameter and length of the 
flow restriction/flow controller tube and the partial vacuum. 
Different applications may require a different flow rate. Thus 
the inner diameter of the flow restriction/flow controller tube 
More specifically, in one possible embodiment the trihy-
droxamate resin has an aluminum-binding constant of 
approximately 1020 . This binding is strong enough to com-
pete with the aluminum-binding ligands present in contami-
nated SVP solutions. However, the rate at which the alumi-
num binds to the resin is a critical factor. This rate can be slow, 
either because of the slow chemical exchange of aluminum 
between the solution and the immobilized chelating agent or 
because of the time required for the solution to pass through 
the porous structure of the resin beads. Thus, a key element in 60 
the design of the filter assembly is the ability to regulate the 
rate of flow ofliquid through the filter assembly 10 to ensure 
sufficient contact time with the resin to produce effective 
aluminum removal. Toward this end, the filter assembly 10 
includes the flow controller 34 built in the control tube aper- 65 
ture36 of the lower spike (see FIG. 3). The inner diameter and 
length of the flow restriction/flow controller tube 34 is 
34 in the present embodiment has been adjusted to produce a 
flow of calcium gluconate of -1 ml/min. For example, where 
the lower spike 17 has a flow restriction/flow controller tube 
34 with an inner flow diameter of about 0.004 inches and a 
length of about 9;16 inches, the flow rate of calcium gluconate 
through the filter is about 1 ml/min. Flow rate will be a 
function of the inner diameter of the flow restriction/flow 
controller tube 34, the length of the flow restriction/flow 
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controller tube 34, the level of vacuum in the second container 
104, the viscosity of the fluid flowing through the filter assem-
bly 10, and other properties of the filter. For example, for eight 
experiments, where the flow restriction/flow controller tube 
inner diameter was 0.004", its length 9 mm and the level of 
vacuum in the second container 104 was negative 27.1±0.1 
inches of mercury in relation to atmospheric pressure, the 
flow rate of calcium gluconate averaged 0.93 ml/min. For six 
experiments, where the flow restriction/flow controller tube 
inner diameter was 0.004", its length 10 mm and the level of 10 
vacuum in the second container 104 was negative 27 inches of 
mercury in relation to atmospheric pressure, the average flow 
rate of calcium gluconate was 0.92 g/min. For twelve experi-
ments, where the flow restriction/flow controller tube inner 
diameter was 0.004", its length 12 mm and the level of 15 
vacuum in the second container 104 was negative 27.5 inches 
of mercury, the average flow rate of calcium gluconate was 
1.25 g/min. When nine experiments were conducted for 
which the inner diameter of the flow restriction/flow control-
ler tube inner diameter was 0.005", its length was varied, and 20 
the level of vacuum in the second container 104 was 26 inches 
of mercury, calcium gluconate flow rate inversely related to 
the length of the flow restriction/flow controller tube (FIG. 4). 
These are examples of the method to control the flow rate 
using two dimensions of the flow restriction/flow controller 25 
tube 34 (internal diameter and length) with the level of 
vacuum in the second container 104. Other dimensions of 
these three variables can be used to achieve the same flow 
rate. Other properties of the filter, such as the membranes, 
also influence the flow rate. 30 
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3. The filter of claim 1 wherein said predetermined rate is 
less than 2.0 ml/min. 
4. The filter of claim 1, wherein said predetermined rate is 
less than 1.0 ml/min. 
5. The filter of claim 1, wherein said predetermined rate is 
about 1.0 ml/min. 
6. The filter of claim 1, wherein said first container con-
nector includes a vented spike and a first set of connector 
clips. 
7. The filter of claim 1, wherein said second container 
connector includes a non-vented spike and a second set of 
connector clips. 
8. The filter of claim 1, wherein said second vial has a 
negative interior pressure. 
9. The filter of claim 1, wherein said flow controller com-
prises a flow restrictor tube having a flow passage with a 
predetermined length L of between about 5 mm and about 20 
mm and a predetermined inner diameter of between about 
0.0508 mm and about 0.1778 mm. 
10. A system for removing a trivalent or tetravalent metal 
ion from a solution, comprising: 
a first container including a solution from which said triva-
lent or tetravalent metal ion is to be removed; 
a second container for receiving a treated solution, said 
second vial having a negative interior pressure; 
a filter assembly for capturing and containing the trivalent 
or tetravalent metal ion, said filter assembly being con-
nected between said first container and said second con-
tainer. 
11. The system of claim 10, wherein said filter assembly 
includes a first connector for said first container and a second 
connector for said second container. 
The amount of resin loaded into the body of the cartridge 
was also varied. In four replicate experiments, 1 g of resin 
removed 91 to 95% of the aluminum from a commercial 
calcium gluconate solution that had an initial AI concentra-
tion of -4,000 micrograms/L. Further tests showed that 800 
mg of resin removed 79% of the AI, and 600 mg of resin 
removed only 64% of theA!. The column/cartridge 12 of the 
present filter assembly 10 has been engineered to hold 1 g of 
resm. 
12. The system of claim 11, wherein said first connector is 
35 a vented spike and a first clamp. 
13. The system of claim 11, wherein said second connector 
is a non-vented spike and a second clamp. 
Since the AI concentration in commercial calcium glucon-
ate solutions can vary, we also tested the present embodiment 
of the filter assembly 10 with calcium gluconate solutions that 
had been spiked with added AI to give total AI concentrations 
14. The system of claim 11, wherein said first connector is 
a vented spike and a first clamp and said second connector is 
40 a non-vented spike and a second clamp. 
15. The system of claim 10, wherein said filter assembly 
includes a flow controller comprising a flow restrictor tube 
having a flow passage with a predetermined length L of 
between about 5 mm and about 20 mm, a predetermined inner of 8,000 and 11,200 micrograms/L. The filter assembly 10 
removed 94% and 90% of the aluminum, respectively, from 
these spiked solutions 
45 diameter D of between about 0.0508 mm and about 0.1778 
mm and said second container has a negative interior pressure 
of between about 84,659.72 pascals and about 94,818.88 
pascals, whereby said flow passage length L, said flow pas-
sage diameter D and said second container pressure P func-
tion together to provide a rate of flow of solution through said 
filter assembly of between about 0.1 ml/min and about 10.0 
ml/min. 
The foregoing has been presented for purposes of illustra-
tion and description. It is not intended to be exhaustive or to 
limit the embodiments to the precise form disclosed. Obvious 
modifications and variations are possible in light of the above 50 
teachings. All such modifications and variations are within 
the scope of the appended claims when interpreted in accor-
dance with the breadth to which they are fairly, legally and 
equitably entitled. 
16. A flow-through filter assembly for removing aluminum 
metal ions from a medical solution including said aluminum 
55 metal ions comprising: What is claimed: 
1. A flow-through filter assembly for removing trivalent 
and tetravalent metal ions from a solution, comprising: 
a housing containing a trihydroxamate chelating resin, said 
housing having an inlet and an outlet; 
a first container connector in fluid communication with 60 
said inlet; 
a second container connector in fluid communication with 
said outlet; and 
a flow controller for limiting flow through said housing to 
a predetermined rate. 
2. The filter of claim 1, wherein said predetermined rate is 
between 0.1 and 10 ml/min. 
65 
a housing including a medical solution inlet; 
an aluminum metal ion capturing agent having anAl-bind-
ing constant of at least -1020 held in said housing; 
a treated medical solution outlet positioned on said housing 
relative to said medical solution inlet to allow for flow of 
medical solution through said filter assembly without a 
mechanical pump; and 
a flow controller for maintaining a rate of flow of medical 
solution through said filter assembly that allows capture 
of aluminum metal ions by said capturing agent. 
17. The filter assembly of claim 16, wherein said rate of 
flow is less than 2.0 ml/min. 
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18. The filter assembly of claim 16, wherein said rate of 
flow is between about 0.1 ml/min and about 10.0 ml/min. 
19. The filter assembly of claim 16, wherein said resin is a 
trihydroxamate chelating resin. 
20. The filter assembly of claim 16, wherein said aluminum 
metal ion capturing agent is selected from a group consisting 
of trihydroxamate chelating resin, desferrioxamine chelating 
resin, tetrahydroxamate chelating resin, hydroxypyridinone 
chelating resin, aminocarboxylate chelating resin, tricatechol 
chelating resin, poly-carboxylate chelating resin and mix- 10 
tures thereof. 
* * * * * 
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